1. Scrip
  2. >>Therapy Areas

Janssen Targets Combinations As Next Step For Newly Approved Darzalex

 
• By Lucie Ellis-Taitt

Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.

Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.

Janssen presented data from the Phase I/II GEN503 study of Darzalex in combination with Celgene's Revlimid, which has been used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.